DMII — Drugs Made In America Acquisition II Corp
NASDAQ · N/A · N/A
- Latest Close
- $10.01
- 30-Day Move
- +1.3%
- Market Cap
- $655M
- Shares Outstanding
- 65,580,000
- ROA
- -219.8%
- Current Ratio
- 0.23
Drugs Made In America Acquisition II Corp
A read-only Alphactor snapshot forDrugs Made In America Acquisition II Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$10.01
30-Day Move
+1.3%
Market Cap
$655M
Shares Outstanding
65,580,000
ROA
-219.8%
Current Ratio
0.23
$10.01
+1.3%last 90 delayed daily bars
90D High
$10.01
90D Low
$9.87
Avg Volume
100,924
DMII is up 1.3% over the last 30 trading days shown on this page.
Latest operating income is $-155,513, which helps anchor the headline ratios with an actual earnings figure.
Dark Pool Short %
70.3%
Latest Close
$10.01
30-Day Move
+1.3%
Market Cap
$655M
Shares Outstanding
65,580,000
ROA
-219.8%
Current Ratio
0.23
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-155,513
Net Income
$-46,158
Gross Margin
--
Net Margin
--
Current Ratio
0.23
Debt / Equity
--
Altman Z
--
N/A
Piotroski
0
Insufficient data
Cash Conversion
--
Rule of 40
--
Insufficient data
Buy Value
$0
Sell Value
$0
Buys
4
Sells
2
Buy Value
$0
Sell Value
$0
Buy/Sell Ratio
2.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2025-09-26 | Do Catherine | J | 100,000 | $0.00 |
| 2025-09-26 | Shulgan Myron W. | J | 100,000 | $0.00 |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | Buy | 700,000 | $0.00 |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | Sell | 7,966,667 | $0.00 |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | J | 400,000 | $0.00 |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | Buy | 700,000 | $0.00 |
| 2025-09-26 | Prasad Sridhar G. | J | 100,000 | $0.00 |
| 2025-09-26 | Stockwell Lynn | Buy | 700,000 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| INVESTMENT MANAGERS SERIES TRUST II-First Trust Merger Arbitrage Fund | 1,779,743 | 0.03% | 2025-12-31 |
| Merger Fund-The Merger Fund | 411,754 | 0.01% | 2025-12-31 |
| INVESTMENT MANAGERS SERIES TRUST II-First Trust Multi-Strategy Fund | 276,206 | 0.00% | 2025-12-31 |
| JNL Series Trust-JNL Multi-Manager Alternative Fund | 22,797 | 0.00% | 2025-12-31 |
| Virtus Event Opportunities Trust-Virtus Westchester Event-Driven Fund | 21,825 | 0.00% | 2025-12-31 |
| Virtus Event Opportunities Trust-Virtus Westchester Credit Event Fund | 15,744 | 0.00% | 2025-12-31 |
| JNL Series Trust-JNL/Westchester Capital Event Driven Fund | 7,973 | 0.00% | 2025-12-31 |
| Merger Fund VL-The Merger Fund VL | 4,141 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
D.E. Shaw
Filed 2026-02-17
$10M
--
Geode Capital Management
Filed 2026-02-09
$265,329
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.